Hydroxyurea (Hydrea)

04/01/2013 - "Hydroxyurea (HU) is highly effective treatment for sickle cell disease (SCD). "
07/01/1997 - "Children with sickle cell anemia provide the best opportunity to assess the efficacy of hydroxyurea (HU) in preventing complications and progressive organ damage. "
12/05/2015 - "Hydroxyurea has proven efficacy in numerous clinical trials as a disease-modifying treatment for patients with sickle cell anemia (SCA) but is currently under-used in clinical practice. "
10/01/2003 - "For patients with sickle cell disease, hydroxyurea is no longer an experimental tool; it has given rise to several trials, where it has proven to be effective in terms of both clinical and haematological improvement."
01/01/2007 - "Although supportive therapies such as regular transfusion and chelation for beta-thal and hydroxyurea (HU) for sickle cell disease have significantly improved clinical manifestations and the quality of life, they cannot eliminate disease and therapy-related complications. "

11/01/2007 - "Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT)."
02/01/2001 - "In a two-year clinical study, we evaluated the efficacy of hydroxyurea in a group of 22 adult Sicilian patients with beta(S)/beta-thalassemia with severe phenotypes. "
10/01/2015 - "We aimed to evaluate the effect of hydroxyurea on clinical and haematological improvement in children with thalassemia intermedia. "
01/01/2015 - "Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports."
03/01/2006 - "Due to genetic heterogeneity of beta-thalassemia (beta-thal) patients, several efforts have been undertaken to determine the efficacy of hydroxyurea treatment. "

08/01/2013 - "Three main themes related to barriers to clinical trial enrollment were identified during analysis of focus groups: general barriers to health related research (general mistrust of research studies, emotional and practical concerns), barriers to trial design (randomization), and barriers to hydroxyurea (long term unknown risks, cancer, myelosuppressive effects). "
08/01/2011 - "This study investigates the differential gene expression profile of JAK2(V617F)-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. "
01/01/2011 - "However, over time, the conclusions from these studies have been called into question and hydroxyurea has been replaced in the standard of care of cervical cancer. "
01/01/2011 - "These studies, mainly in cervical cancer, initially produced a great deal of interest, leading to the incorporation of hydroxyurea in the treatment protocols of many institutions. "
08/01/2000 - "In this study, we have observed an interesting effect of hydroxyurea on tumor cells: an induction of senescence-like changes. "

05/01/2015 - "Opioid users used hydroxyurea more often than nonusers, even when controlling for mean pain on pain days. "
02/01/2015 - "The ratio between apelin and Big ET was negatively correlated to caregiver ratings of baseline pain and positively correlated to history of VOEs, which is possibly due to hydroxyurea treatment. "
12/01/2014 - "As hydroxyurea benefits some MCAS patients (particularly SCA-like pain), its benefit in SCA may be partly attributable to treatment of unrecognized MCAS. "
07/01/2014 - "We found no significant association between GST genotypes and frequency of sickle cell-related pain, transfusion frequency, disease severity, or hydroxyurea treatment. "
02/01/2014 - "Analyses of longitudinal pain trajectories suggest several different pain trajectories, differing in their frequency, age of onset, and age at peak pain frequency with clinical implications for hydroxyurea management."

02/01/1998 - "To manage the current case of polycythemia vera, hydroxyurea was effective for the control of hematocrit and transfusion of platelet concentrates was effective for hemostasis."
03/01/1987 - "Because hydroxyurea is safe and effective in the treatment of polycythemia vera, it should be considered as first-line therapy. "
08/01/2006 - "The cytoreductive agent of choice for these disorders is currently hydroxyurea, emerging from randomized trials beginning with those of the Polycythemia Vera Study Group. "
11/01/2015 - "Assessing The Level Of Resistance/Intolerance To Hydroxyurea Therapy Amongst Patients With Polycythemia Vera In Europe."
11/01/2015 - "Symptoms, Concomitant Conditions And Cardiac Risk In European Hydroxyurea Treated Polycythemia Vera Patients."